MONTVALE, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will participate in the conference. About Balchem Corp ...

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a hybrid presentation followed by an analyst-led Q&A session at the TD Cowen 46th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA on Wednesday, March 4, 20 ...

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by excess neural excitability, today announced that the Company’s management will participate in three upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference – Wednesday, February 25th at 11:20 am ET46th Annual TD Cowen Health Care Conference – Wednesday, March 4th at 9:50 am ETLeeri ...

First‑time outsourced operations for Europe’s leading lingerie brand, delivering a streamlined, technology‑driven, multi‑channel logistics solution ALMERE, The Netherlands, Feb. 25, 2026 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure‑play contract logistics provider, today announced the successful launch of its new partnership with Hunkemöller, one of Europe’s leading lingerie brands. GXO began managing Hunkemöller’s logistics operations in Almere as of January 1, 2026, markin ...

BROOKFIELD, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Photronics, Inc. (NASDAQ:PLAB), a worldwide leader in photomask technologies and solutions, today reported financial results for its first quarter of fiscal year 2026 ended February 1, 2026. Commenting on the first quarter performance, Chairman and CEO George Macricostas said, “Photronics delivered strong results in our fiscal first quarter achieving record high-end IC revenue for the second consecutive quarter. We remain on track with our facility expans ...

BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in March 2026: TD Cowen 46th Annual Healthcare ConferenceCompany PresentationPresenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsDate: Wednesday March 4, 2026Place: Boston Marriott Cop ...

Core Insights - Geron Corporation reported a net product revenue of $48 million for Q4 2025 and $184 million for the full year 2025, indicating a growth in demand for RYTELO [1][5] - The company ended 2025 with approximately $401 million in cash and marketable securities, down from $503 million in 2024 [4][22] - Geron reiterated its financial guidance for 2026, expecting RYTELO net product revenue between $220 million and $240 million, and total operating expenses between $230 million and $240 million [1][14] Financial Performance - Total product revenue for Q4 2025 was $48 million, compared to $47.5 million in Q4 2024, while full-year revenue increased from $76.5 million in 2024 to $183.6 million in 2025 [7][8] - The company reported a net loss of $31.1 million for Q4 2025, compared to a net loss of $25.4 million in Q4 2024, and a total net loss of $85.8 million for the full year 2025, down from $174.6 million in 2024 [5][6] - Total operating expenses for 2025 were $255 million, slightly above the previous year's $250.7 million [9] Operational Highlights - RYTELO demand grew by 9% in Q4 2025 compared to Q3 2025, with an increase of 150 ordering accounts, bringing the total to approximately 1,300 [5] - The company is focusing on driving U.S. commercial growth and exploring international opportunities for RYTELO, supported by FDA approval and scientific evidence [2][22] - Geron is preparing for the IMpactMF interim analysis in relapsed/refractory myelofibrosis and anticipates initial data from real-world experience trials in lower-risk MDS in the second half of 2026 [2] Cost Management - Research and development expenses decreased to $73.7 million in 2025 from $103.7 million in 2024, primarily due to lower clinical trial costs following RYTELO's approval [11] - Selling, general, and administrative expenses increased to $159.3 million in 2025 from $145.7 million in 2024, attributed to higher sales and marketing investments [12] - Restructuring charges of $17 million were incurred in 2025 due to a workforce reduction of approximately one-third of the staff [13]

VANCOUVER, British Columbia, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Coppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF, FSE: 9I3) (“Coppernico” or the “Company”), is pleased to report initial results from the recently completed gravity, magnetic, and high-resolution photogrammetry surveys covering the area between Antapampa and Tipicancha at its Sombrero Project in Peru (Figure 1). These high-resolution datasets significantly increase confidence in subsurface geological interpretation and refine the three-dimension ...

Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDA ...

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 a.m. ET. A live webcast of the event will be available in the Investors section of ...